[
    [
        {
            "time": "",
            "original_text": "十大上市药企透视：恒瑞医药归母净利润居首 华润三九销售费用率高企",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "归母净利润",
                    "华润三九",
                    "销售费用率"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "十大上市药企透视：恒瑞医药归母净利润居首 华润三九销售费用率高企",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "民族品牌指数上涨0.03% 白云山领涨",
            "features": {
                "keywords": [
                    "民族品牌指数",
                    "上涨",
                    "白云山",
                    "领涨"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "民族品牌指数上涨0.03% 白云山领涨",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "造假300亿的康美药业将易主，谁敢接？绯闻接盘方出来了",
            "features": {
                "keywords": [
                    "康美药业",
                    "造假",
                    "易主",
                    "绯闻接盘方"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "造假300亿的康美药业将易主，谁敢接？绯闻接盘方出来了",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 10,
                "Source_Recency": 9
            }
        }
    ]
]